Hence, clinical trials with selective enrolment are needed to shed more light on the clinical benefits of combined HER2 and PI3K/AKT/mTOR targeted therapy in tumours with PI3K/AKT pathway hyperactivation, including IRS4+ tumours. This evidence concerns the gene AKT1 and neoplasm.